Commentary: On the levels of patient selection in registry-based randomized controlled trials.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
04 Feb 2019
Historique:
received: 30 04 2018
accepted: 18 01 2019
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 14 6 2019
Statut: epublish

Résumé

Registry-based randomized controlled trials (RCTs) are presumed to include a less-selected patient population and thus to have enhanced generalizability compared to conventional RCTs. However, this view disregards the levels of patient selection in registry-based RCTs: the registry selection level and the trial selection level. At both levels, systematic selection can occur and generalizability can be diminished. Nevertheless, using a registry as a basis for recruitment, randomization, and data collection results in an advantage: the trial selection takes place within the registry framework, where baseline characteristics of non-enrolled patients are automatically documented as well. By comparing the baseline variables of the enrolled and non-enrolled patients, the trial selection can always be investigated, which gives a sound basis for discussing the generalizability to the registry population.

Identifiants

pubmed: 30717778
doi: 10.1186/s13063-019-3214-x
pii: 10.1186/s13063-019-3214-x
pmc: PMC6360703
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

100

Références

J Clin Psychopharmacol. 2000 Dec;20(6):699-702
pubmed: 11106145
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
PLoS Clin Trials. 2006 May;1(1):e9
pubmed: 16871331
JAMA. 2008 Jan 30;299(4):409-16
pubmed: 18230778
Int J Epidemiol. 2010 Feb;39(1):89-94
pubmed: 19376882
Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):86-94
pubmed: 19961477
Lancet. 2010 Mar 27;375(9720):1090-9
pubmed: 20231034
Heart. 2010 Oct;96(20):1617-21
pubmed: 20801780
Am Heart J. 2010 Dec;160(6):1042-8
pubmed: 21146656
Circulation. 2011 Aug 2;124(5):544-54
pubmed: 21709065
J Am Coll Cardiol. 2011 Aug 23;58(9):915-22
pubmed: 21851879
Circulation. 2012 Mar 13;125(10):1246-55
pubmed: 22308301
Lancet. 2013 Feb 23;381(9867):661-9
pubmed: 23374649
N Engl J Med. 2013 Oct 24;369(17):1587-97
pubmed: 23991656
N Engl J Med. 2013 Oct 24;369(17):1579-81
pubmed: 23991657
Lancet Oncol. 2013 Oct;14(11):1077-1085
pubmed: 24028813
N Engl J Med. 2014 Sep 18;371(12):1111-20
pubmed: 25176395
Circulation. 2015 Jan 6;131(1):34-42
pubmed: 25406305
Lancet. 2015 Apr 18;385(9977):1527-35
pubmed: 25601789
Nat Rev Cardiol. 2015 May;12(5):312-6
pubmed: 25781411
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
J Clin Epidemiol. 2016 Dec;80:16-24
pubmed: 27555082
Curr Heart Fail Rep. 2017 Apr;14(2):59-70
pubmed: 28247180
Trials. 2017 Apr 5;18(1):163
pubmed: 28381291
J Clin Epidemiol. 2018 Jan;93:120-127
pubmed: 28951111
J Clin Psychopharmacol. 1996 Apr;16(2):170-6
pubmed: 8690832

Auteurs

Florian Lasch (F)

Department of Biostatistics, Hannover Medical School, Carl-Neuberg Strasse 1, 30165, Hannover, Germany. Lasch.florian@mh-hannover.de.

Kristina Weber (K)

Department of Biostatistics, Hannover Medical School, Carl-Neuberg Strasse 1, 30165, Hannover, Germany.
F. Hoffmann-La Roche AG, MDBD, Bldg 663, Hochstrasse, CH-4070, Basel, Switzerland.

Armin Koch (A)

Department of Biostatistics, Hannover Medical School, Carl-Neuberg Strasse 1, 30165, Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH